FDA clears Interlace Medical's MyoSure
This article was originally published in Clinica
Executive Summary
MyoSure, a hysteroscopic tissue removal system developed by Interlace Medical for the removal of submucosal fibroids and polyps has received US FDA 510(k) clearance. The MyoSure system enables quick removal of fibroids in a single step, avoiding risks associated with energy-based devices, Framingham, Massachusetts-based Interlace claims. The minimally-invasive procedure preserves uterine form and function. Nearly 80% of women will develop fibroids in their lifetime.